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ABSTRACT 
SEARCHING FOR NOVEL LIGANDS FOR THE CANNABINOID 
AND RELATED RECEPTORS 
Pritesh Prakash Kumar 
September 14,2011 
A cell-based, Homogenous Time Resolved Fluorescence (HTRF) method was 
optimized and used to test a library of 60 putative endocannabinoids for activity towards 
CB1 or CB2, and to test cannabinoid ligands and fatty acid amides for GPRl19 by 
measuring cAMP levels in this study. The Z' factors for the assay were greater than 0.5 
for all three receptors and the assay was able to can tolerate up to 1 % DMSO 
demonstrating a robust and suitable technology for screening. The known cannabinoid 
and GPRl19 agonists exhibited the rank order of potency expected for 
CB1/CB2/GPRl19. Our data demonstrate that none of the amides, N-acyl amino acids 
(glycine and alanine) Acyl-dopamines, and Acyl-GABAs was able to activate either CB1 
or CB2. However the ethanoamides Dihomo-gamma-linolenoyl ethanolamide (DLEA) 
and DTEA Docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl ethanolamide (DTEA) were found to 
activate CB 1 and CB2. Our data provide direct evidence to support the hypothesis that 
unsaturation in the acyl chain of fatty acid ethanolamides affects the ability of these 
v 
compounds to activate GPRl19. Our results suggested that GPRl19 activation requires 
certain structural requirements for the charged head groups of the fatty acid amides. 
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Marijuana (Cannabis sativa) is one of the oldest and most widely abused drugs, 
which has also been used for medicinal purposes by various cultures. The primary 
psychoactive constituent of marijuana is ~9-tetrahydrocannabinol (~9-THC) (Gaoni and 
Mechoulam, 1971). The recognized central nervous system (CNS) responses to 
cannabinoids include alterations in cognition, memory, and motor function and 
dysphoria/euphoria, and sedation (Hollister, 1986). 
In addition to psychotropic activity, ~9 -THC and other cannabinoids produce a 
variety of effects with therapeutic potential, e.g., analgesia, anti-nausea, anti-convulsion, 
anti-inflammation and lowering intraocular pressure (Goutopoulos and Makriyannis, 
2002; Hollister, 1986). During the past two decades, a major investigative effort on the 
mechanisms of action of cannabinoids has been launched. Cannabinoids have been found 
to act through G-protein coupled receptors on cell membranes (Childers and Breivogel, 
1998; Childers and Deadwyler, 1996; Devane et a1., 1988; Howlett, 1995). Several 
cDNAs and genes encoding cannabinoid (CB) receptors have been cloned, including CBl 
and CB2 (Matsuda et a1., 1990; Mumo et a1., 1993). Endogenous cannabinoid ligands 
have been isolated from the brain (Devane et a1., 1992a); high affinity cannabinoid 
mimetics with a variety of chemical structures have been synthesized, and subtype-
selective ligands for cannabinoid receptors are becoming available (Huffinan, 2000; 
Palmer et a1., 2002). 
Cannabinoid Receptor Expression 
CB 1 receptors are primarily distributed in the CNS (brain and spinal cord) and 
peripheral nervous system (Grotenhermen, 2004). CBl receptor expression has also been 
found in several peripheral organs and tissues including endocrine glands, leukocytes, 
spleen, heart and parts of the reproductive, urinary and gastrointestinal tracts 
(Grotenhermen, 2004). In the CNS, CBl is highly expressed in the basal ganglia, globus 
pallidus, entopeduncular nucleus, substantia nigra pars reticulata, caudate-putamen, 
cerebral cortex, cerebellum, hippocampus and dorsal primary afferent spinal cord regions 
(Pertwee, 2005). 
CB2 receptors are primarily located in immune cells, which include neutrophils, 
monocytes, natural killer cells, T cells, B cells, macrophages, mast cells, and microglia 
(Pertwee, 2005). CB2 receptors have also been detected in the spleen and tonsils 
(Pertwee, 2005). CB2 is thought to mediate many of the immumnomodulatory properties 
produced by cannabinoids. 
Cannabinoid Receptor Signaling 
The cannabinoid receptors activate multiple signal transduction pathways. CB 1 
and CB2 receptor agonists inhibit forskolin-stimulated adenylyl cyclase by activation of a 
pertussis toxin-sensitive G-protein (Felder et aI., 1995). Stimulation of adenylyl cyclase 
has been reported in pertussis toxin-treated cells, suggesting that in the absence of 
functional Gila coupling, the CBl receptor can activate Gs (Felder et aI., 1998; Glass and 
Felder, 1997; Maneuf and Brotchie, 1997). It has been reported that activation of the CB2 
receptor can produce stimulation of cAMP formation, as well (Rhee et aI., 1998). Both 
CB 1 and CB2 receptors are also coupled to the MAP kinase cascade via Gila proteins 
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(Bouaboula et aI., 1995). In heterologous cells, CB 1 but not eB2 receptors inhibit L-, N-, 
P-, and Q- type calcium channels and activate inwardly rectifying potassium channels 
(Caulfield and Brown, 1992; Felder et aI., 1995; Gebremedhin et aI., 1999; Henry and 
Chavkin, 1995; Mackie and Hille, 1992; Mackie et aI., 1995; Pan et aI., 1996). 
Exogenously expressed CBl receptors couple to the inwardly rectifying GIRK channels 
in AtT -20 pituitary tumor cells in a pertussis toxin-sensitive manner, indicating that Gila 
proteins serve as transducers of the response (Henry and Chavkin, 1995; Mackie et aI., 
1995). Inhibition of calcium channels and enhancement of inwardly rectifying potassium 
currents are pertussis toxin-sensitive, but independent of cAMP inhibition, suggestive of 
a direct G protein mechanism (Mackie and Hille, 1992; Mackie et aI., 1995). 
Cannabinoid Receptor Agonists 
Based on their chemical structures, cannabinoid agonists can be classified into at 
least four groups: the classical cannabinoids such as (-)_~9 -THC and HU -210 (Little et 
aI., 1989; Mechoulam et aI., 1988), the non-classical cannabinoids typified by CP-55,940 
(D'Ambra et aI., 1992; Melvin et aI., 1995), the aminoalkylindoles (AAIs) typified by 
WIN-55,212-2 (Compton et aI., 1992; Ward et aI., 1990) and the endogenous 
cannabinoids. The non-classical cannabinoids clearly share many structural features with 
the classical cannabinoids, e.g. a phenolic hydroxyl at C-l (C2 '), and alkyl side chain at 
C-3 (C-4'), as well as, the ability to adopt the same orientation of the carbocyclic ring as 
that in classical cannabinoids (Reggio et aI., 1993). The AAIs, on the other hand, bear no 
obvious structural similarities with the classical/non-classical cannabinoids. 
The first identified endogenous cannabinoid ligand, isolated first from brain, was 
arachidonylethanolamide (AEA, also called anandamide) (Devane et aI., 1992b). sn-2-
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arachidonyl glycerol (2-AG); was first isolated from intestinal tissue and shown to be a 
second endogenous cannabinoid ligand (Mechoulam et aI., 1995). 2-AG has been found 
to be present at concentrations 170 times greater than anandamide in the brain (Stella et 
aI., 1997). In addition, the fatty acid glycerol ether, 2-arachidonyl glyceryl ether has been 
suggested to be another endogenous cannabinoid ligand (Stella et aI., 1997). 
The cannabinoid agonists have been shown to have potential therapeutic uses as 
appetite stimulants, analgesics, anti-emetics, anti-spasmodic, anti-proliferative, anti-
inflammatory, and anti-glaucoma agents (Goutopoulos and Makriyannis, 2002; Hollister, 
1986; Pertwee, 2000; 2001 a; b; Piomelli et aI., 2000; Sanchez et aI., 2001). The side 
effects accompanying the therapeutic responses of cannabinoid agonists include 
alterations in cognition, memory, and motor functions, dysphoria/euphoria, and sedation 
(Abood and Martin, 1992; Hollister, 1986). 
Cannabinoid Receptor Antagonists 
Rinaldi-Carmona and co-workers at Sanofi developed the first CB 1 antagonist, 
SR141716A (Rinaldi-Carmona et aI., 1994). SR141716A displays nanomolar CBl 
affinity (Ki =1.98± 0.13 nM), but very low affinity for CB2. In vitro, SR141716A 
antagonizes the inhibitory effects of cannabinoid agonists on adenylyl cyclase activity in 
rat brain membranes. SR141716A also antagonizes the pharmacological and behavioral 
effects produced by CBI agonists after interperitoneal or oral administration (Barth and 
Rinaldi-Carmona, 1999). Other CBI antagonists have been reported, including AM-630 
(Hosohata et aI., 1997a; Hosohata et aI., 1997b; Pertwee et aI., 1995), L Y-320135 (Felder 
et aI., 1998) and 0-1184 (Ross et aI., 1998). 
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Rinaldi-Cannona and co-workers at Sanofi also reported the first CB2 antagonist, 
SR144528 (Barth and Rinaldi-Cannona, 1999; Rinaldi-Cannona et al., 1998). SR144528 
displays sub-nanomolar affinity for both the rat spleen and cloned human CB2 receptors 
(Ki = 0.60±0.13 nM). SR-144528 displays a 700-fold lower affinity for both the rat brain 
and cloned human CB 1 receptors. 
There is strong evidence in the cannabinoid literature that SR141716A and 
SR144528 can act as inverse agonists. Moreover, both CB1 and CB2 receptor-transfected 
cells exhibit high constitutive activity (Bouaboula et al., 1999; Bouaboula et al., 1997). 
This constitutive activity can be blocked by the CB1-selective SR141716A and CB2-
selective SR144528, respectively. Recently, therapeutic applications for cannabinoid 
inverse agonists are emerging in the literature. For example, the CB1 inverse agonist, 
SR 141716A has been developed as an appetite suppressant. 
The Cannabinoid Related Receptor: GPRl19 
Type 2 diabetes (T2D) and associated obesity are growing public health concerns 
(Shah, 2009). As a result, many phannaceutical companies have focused their efforts to 
discover novel, orally effective agents that can modulate glucose homeostasis with a 
concurrent reduction in body weight. GPR119 is a member of the rhodopsin family ofG 
protein-coupled receptors. Recently GPR119 has emerged as a promising therapeutic 
target for both T2D and obesity (Overton et al., 2008). 
GPR119 Structure 
Homology clustering analysis revealed that the closest relatives ofGPR119 are 
the cannabinoid receptors (Overton et al., 2006). In addition, through phylogenetic 
analysis, Godlewski et al 2009 placed GPR119 to the MECA (melanocortin; endothelial 
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differentiation gene; cannabinoid; adenosine) receptor cluster and confirmed that the 
closest relatives of GPR119 are CB 1 and CB2 cannabinoid receptors (Godlewski et aI., 
2009). 
GPRl19 Receptor Expression 
GPR119 is primarily expressed in pancreatic beta-cells and enteroendocrine cells 
of the gastrointestinal tract (GI) (Chu et aI., 2007b; Lauffer et aI., 2009; Soga et aI., 
2005). Immunohistochemical and autoradiographic data demonstrate that GPR119 is 
mainly localized to a subset of cells in the pancreatic islets of Langerhans where it was 
found to co-localize with insulin (Chu et aI., 2007b). GPRl19 immunoreactivty was also 
found in the small intestine where it co-localizes with glucagon-like-peptide-l (GLP-l) 
(Chu et aI., 2007b). In addition, GPR119 has been found in the following pancreatic beta 
cell lines: NIT-I, MIN6, RIN5, HIT-TIS (Chu et aI., 2007b; Lan et aI., 2009; Ning et aI., 
2008; Reimann et aI., 2008; Soga et aI., 2005). Furthermore, GPR119 was found in 
enteroendocrine L-cell models such as FRIC, mGLUTag, and hNCI-H716 and in mouse 
L-cell primary cultures (Chu et aI., 2007b; Lan et aI., 2009; Ning et aI., 2008; Reimann et 
aI., 2008; Soga et aI., 2005). 
Although it has not been detected in the human CNS, GPR119 expression has 
been detected in several regions of the rat brain, including cerebellum, cerebral cortex, 
choroid plexus, hippocampus and hypothalamus (Jones et aI., 2009). 
GPR119 Receptor Signaling 
GPRl19-expressing cells display a constitutive increase in intracellular cAMP 
suggesting that this receptor is coupled to the stimulatory G-protein (Gs) (Chu et aI., 
2007b). It has been shown that GPRl19 agonists activate adenylyl cyclase, increase 
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cAMP, and increase protein kinase A activity in GPRl19-expressing cells (Chu et aI., 
2007b; Lauffer et aI., 2009; Reimann et aI., 2008; Semple et aI., 2008; Soga et aI., 2005). 
In addition to Gs coupling, there is evidence for GPRl19-mediated activation of ATP-
sensitive K + and voltage-dependent Ca2+ channels (Ning et aI., 2008). 
GPR119 Endogenous Agonists 
Oleoylethanolamide (OEA) was the first putative endogenous fatty acid 
ethanolamide ligand reported for GPRl19 (Overton et aI., 2006). Overton and coworkers 
have also tested the endogenous cannabinoid agonist AEA and the saturated fatty-acid 
ethanolamide palmitoylethanolamide (PEA) for GPRl19 activity in a yeast-based assay. 
Their results showed that OEA was the most efficacious to activate GPRl19, followed by 
PEA and then AEA (Overton et aI., 2006). 
In an attempt to identify novel ligands for GPRl19 more than 3000 endogenously 
produced compounds were screened for GPRl19 activity (Chu et aI., 2010). Among the 
compounds tested, several fatty acid amides were found to be active. OEA was confirmed 
to be a GPRl19 agonist. Oleamide, an endogenously produced free amide displayed 
agonist activity for GPRl19. In addition, N-oleoyldopamine (OLDA) activated GPRl19 
with a similar potency to OEA (Chu et aI., 2010). 
Very recently, Hansen et aI. (2011) indentified a dietary fat-derived naturally 
occurring 2-0leoyl glycerol (2-0G), as a GPR119 agonist. It was also shown that 2-0G 
administration to fasting humans led to increased glucagon-like peptide-1 (GLP-1) 
secretion (Hansen et aI., 2011). 
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GPR119 Synthetic Agonists 
High-throughput screening in the pharmaceutical industry resulted in the 
identification ofPSN632408 and AR231453, two prototypical oxadizone analogues, as 
synthetic GPRl19 agonists (Semple et aI., 2008). AR231453 is notable for its nanomolar 
affinity for GPR 119. Both of these compounds have been shown to increase intracellular 
cAMP, and enhance the secretion of insulin and GLP-1 (Semple et aI., 2008). Currently, 
the one synthetic GPRl19 agonist, APD668 (Arena Pharmaceuticals), has entered clinical 
trials. 
GPR119: Diabetes and Obesity 
Since GPRl19 is primarily distributed in pancreatic ~-cells and enterocrine L-
cells, it was hypothesized that this receptor may modulate glucose homeostasis and 
obesity (Overton et aI., 2006). 
It has been shown previously that GPRl19 agonists (synthetic and endogenous) 
stimulate insulin release by at least two mechanisms (Flock et aI., 2011). The first 
mechanism is that the increase in cAMP signaling directly leads to an enhanced glucose-
dependant insulin secretion. The second mechanism is that the increase in cAMP 
signaling results in increased glucagon-like peptide 1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP) levels, which stimulates glucose-dependant insulin secretion 
and also inhibits glucagon secretion, appetite, and delays gastric emptying (Lauffer et aI., 
2008). 
Recently, endogenous and small molecule synthetic GPRl19 agonists have been 
shown to stimulate insulin release (Chu et aI., 2007b; Overton et aI., 2006; Soga et aI., 
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2005). These data suggest that orally effective GPR119 agonists may be used to improve 
glucose homeostasis. 
It has been demonstrated that AR231453 increased secretion of insulin and GLP-l 
in vitro (Chu et aI., 2008; Semple et aI., 2008). In addition, it has been shown that in vivo 
administration of AR231453 stimulated GLP-1 secretion, as well as improved glucose 
tolerance directly by acting on pancreatic ~-cells to enhance glucose-dependant insulin 
release (Chu et aI., 2008). Furthermore, the insulinotropic effect of AR231453 was 
completely lost in GPRl19-deficient mice, demonstrating the involvement of GPR119 
(Chu et aI., 2007a) . 
It has been shown that OLDA also stimulated insulin release in HIT -T15 
(Hamster insulinoma cell line) cells expressing GPR119 (Chu et aI., 2010). It was further 
shown that OLDA improves glucose handling in mice in a GPRl19-dependent manner, 
because OLDA increased glucose tolerance in control mice and had virtually no effect 
on glucose tolerance in GPRl19-deficient mice (Chu et aI., 2010). 
In addition to diabetes, GPR 119 is also a potential target for the treatment of 
obesity (Overton et aI., 2006). Both the synthetic GPR119 agonist PSN632408 and the 
putative endogenous GPR119 agonist OEA possess hypophagic properties (Lan et aI., 
2009; Overton et aI., 2006). In contrast to OEA, PSN632408 displayed no activity 
towards Peroxisome Proliferator-Activated Receptor alpha (PPARa) (Overton et aI., 
2006). The hypophagic effects ofOEA may not be mediated by GPR119 since the effect 
was the same in GPRl19-defecient mice indicating that OEA and PSN632408 do not act 
through similar mechanisms (Lan et aI., 2009). 
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CHAPTER 2 
OPTIMIZATION, VALIDATION, AND APPLICATION OF A CELL-BASED 
SCREENING TECHNOLOGY FOR SEARCHING NOVEL LIGANDS FOR 
THE CANNABINOID RECEPTORS CBl AND CB2 
INTRODUCTION 
The cannabinoid receptors and endocannbinoids have been shown to be involved 
in numerous pathological conditions (Miller and Devi, 2011). Thus, the discovery of new 
cannabinoid ligands may lead to novel therapeutic approaches for a wide range of 
diseases. 
The purpose of this study was two-fold: 1) To develop and optimize a cell-based 
cAMP assay for screening novel CB 1 and CB2 ligands; 2) To test a library of 60 putative 
endocannabinoids for their activities towards CB 1 and CB2. 
The first purpose of the current study was to develop and optimize an assay 
appropriate for searching novel ligands for CB 1 and CB2. There are many cAMP assays 
available for screening purposes. Homogenous Time Resolved Fluorescence (HTRF) is 
based on the principle of competition of antibody binding sites between the native cAMP 
produced by cells and the d2-labeled cAMP (Gabriel et aI., 2003). One distinct advantage 
of this assay over the other technologies is HTRF's ratiometric measurement. In this 
assay, measurements are taken at two wavelengths (620 and 655 nrn), which allows for 
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the ratiometric reduction of data. The donor (Eu3+ Cryptate) emits at 620 nm while the 
acceptor (d2) emits at 665 nm. The donor measurement serves as an internal reference 
while emissions from acceptor are indicators of biological reaction. This feature is 
extremely advantageous because it allows the reduction of well-to-well variation and it 
eliminates the interference of compound autofluorescence. This assay has been 
successfully miniaturized and still maintains accuracy and reproducibility. It is non-
radioactive and does not require separation or washing steps. It is not labor intensive, is 
cost-effective, and has high sensitivity in the upper femtomolar range. These qualities 
make the cell-based HTRF cAMP assay the assay of choice to develop and optimize for 
this thesis. 
The second purpose of this current study was to test a library of 60 putative 
endocannabinoids for activity towards CB 1 or CB2. We choose this library for our initial 
screening experiments because all the ligands in the library are structurally related to the 
endocannabinoid AEA, but each compound has some distinct structural features. These 
ligands differ in their degree of saturation, fatty acid chain length, and head group 
composition. The ligands consist of 10 different fatty acids with 6 different polar head 
groups. Several distinct chemical classes were tested in this study, including amides, 
ethanolamides, lipo-amino acids, acyl-GABAs, and acyl-dopamines. By examining the 
activity of these 60 compounds towards CBl and CB2, we tested our hypothesis that 
these ligands with structures related to AEA may activate these receptors. 
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MATERIALS AND METHODS 
Materials 
Dulbecco's Modified Eagles's Medium (DMEM), penicillin/streptomycin, L-
glutamine, trypsin, and geneticin were purchased from Mediatech (Manassas, VA). Fetal 
Bovine Serum was obtained from Atlanta Biologicals (Lawrenceville, GA). Glass tubes 
used for cAMP accumulation assays were obtained from Kimble Chase (Vineland, NJ). 
These tubes were silanized by exposure to dichlorodimethylsilane (Sigma-Aldrich, St. 
Louis, MO) vapor for 3 h under vacuum. 
384-well, round bottom, low volume white plates were purchased from Grenier 
Bio One (Monroe, NC). A cell-based cAMP HiRange kit was purchased from CisBio 
International (Bedford, MA). 
An endocannabinoid library containing 60 compounds pre-dissolved in DMSO 
solutions was purchased from Enzo Life Sciences (Farmingdale, NY). CP-55, 940, WIN-
55,212-2, HU-210, 2-arachidonoyl glycerol, and anandamide were purchased from 
Tocris Bioscience (Ellisville, MO). Forskolin was obtained from Sigma-Aldrich (St. 
Louis, MO). RO 20-1724 was purchased from Enzo Life Sciences (Farmingdale, NY). 
Cell Transfection and Culture 
Human Embryonic Kidney 293 (HEK293) cells were maintained in Dulbecco's 
Modified Eagle Medium (DMEM) containing 10% fetal bovine serum, 2mM glutamine, 
100 units/ml penicillin, and 100 /lg/ml streptomycin in a humidified atmosphere 
consisting of 5% C02, at 37°C. Expression plasmids containing the wildtype cannabinoid 
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receptors were stably transfected into HEK293 cells using lipofectamine, according to 
manufacturer's instructions. Stably transfected cells were selected in culture medium 
containing 800 Ilg/ml geneticin. Having established cell lines stably expressing wildtype 
CB 1 and CB2 receptors, the cells were maintained in growth medium containing 400 
Ilg/ml of geneticin until needed for experiments. 
Cell-based HTRF cAMP assay 
Cellular cAMP levels were measured using reagents supplied by Cisbio 
International (HTRF HiRange cAMP kit). Cultured cells were washed twice with 
phosphate-buffered saline (8.1 mM NaH2P04, 1.5 mM KH2P04, 138 mM NaCI, and 2.7 
mM KCI, pH 7.2), and then dissociated in phosphate-buffered saline containing 1 mM 
EDT A. Dissociated cells were collected by centrifugation for 5 min at 2000g. The cells 
were resuspended in cell buffer (DMEM plus 0.2 % fatty acid free bovine serum 
albumin) and centrifuged a second time at 2000g for 5 min at 4°C. Subsequently, the 
cells were resuspended in an appropriate final volume of cell buffer plus the 
phosphodiesterase inhibitor R020-1724 (2 IlM). 5000 cells were added at 5 III per well 
into 384-well, round bottom, low volume white plates (Grenier Bio One). Compounds 
were diluted in drug buffer (DMEM, plus 2.5 % fatty acid free bovine serum albumin and 
2 IlM forskolin) and added to the assay plate at 5 III per well. Following incubation of 
cells with the drugs or vehicle for 7 minutes at room temperature, d2-conjugated cAMP 
and Europium cryptate-conjugated anti-cAMP antibody were added to the assay plate at 5 
III per well. After 2 hour incubation at room temperature, the plate was read on a TECAN 




Data analyses were perfonned based on the ratio of fluorescence intensity of each 
well at 620nm and 665 nm. Data are expressed as delta F%, which is defined as 
[(standard or sample ratio - ratio of the negative control) / ratio of the negative control] x 
100. The standard curves were generated by plotting delta F% versus cAMP 
concentration using non-linear least squares fit (Prism software, GraphPad, San Diego, 
CA). Unknowns were detennined from the standard curve as nanomolar concentrations 
of cAMP. The data from the cAMP assays were (~xpressed as percentage of forskolin-
stimulated cAMP accumulation. After the unknowns were detennined, the sigmoidal 
concentration-response equations were used (via GraphPad Prism) to detennine ECso and 
Emax values of the tested compounds. 
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RESULTS 
Z' Factor Determination 
To detennine the Z' value, experiments were perfonned in 384-well plates using 
many replicates of the HTRF cell-based cAMP assay with positive and negative controls. 
F or positive controls, the HEK293 cells expressing CB 1 (Fig. 2.1) or CB2 (Fig. 2.2) were 
treated with the potent mixed CB1/CB2 agonist CP-55,940 at a concentration of 100 nM 
for 7 minutes at room temperature. For negative controls, the cells were treated with 
vehicle for 30 minutes. The Z' value was calculated using the fonnula: Z' = 1-3[(standard 
deviation of negative control) + standard deviation of positive control)] I [(mean of 
negative control) - (mean of positive control)] (Zhang et aI., 1999). In the current study, 
the Z factor was detennined to be 0.77 and 0.79, respectively, for CB1 and CB2. 
Tolerance to Dimethyl Sulfoxide (DMSO) 
One important condition to define is the concentration of dimethyl sulfoxide 
(DMSO) that the HTRF cAMP assay is able to tolerate without any loss in signal. For 
this purpose, we tested the effect ofDMSO at concentrations ranging from 0.001 % to 100 
%. In the present study, we have shown that the HTRF cAMP assay can tolerate DMSO 
up to 1.0 % for both CB 1 (Fig. 2.3) and CB2 (Fig. 2.4) without any loss of signal. 
Forskolin Optimization 
In order to detennine the optimal forskolin concentration to be used to stimulate 
cAMP production, forskolin concentration-response experiments were perfonned for 
both HEK293 cells stably expressing CB 1 and HEK293 cells stably expressing CB2. 
With concentrations ranging from 0.01 nM to 100 IlM, forskolin increased cAMP 
accumulation in both CB I-expressing cells (Fig. 2.5) and CB2-expressing cells (Fig. 2.6). 
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The forskolin ECso values for CB I-expressing cells and CB2-expressing cells were 
determined to be 1.39 (0.60 to 3.00) IlM and 0.76 (0.52 to 1.10) IlM, respectively. 
Pharmacological Testing of Known Cannabinoid Agonists 
The ability of known cannabinoid agonists to activate cannabinoid receptors was 
tested in a functional cAMP accumulation assay (HTRF) via HEK293 cells stably 
expressing either CBl or CB2. As shown in Fig. 2.7, in HEK293 cells stably expressing 
CBl, all five previously reported cannabinoid ligands, HU-210, CP-55,940, WIN-55,212-
2, AEA, and 2-AG, inhibited forskolin-stimulated cAMP accumulation in a 
concentration-dependant manner, with a rank order of potency ofHU-210 > CP-55,940 > 
WIN-55,212-2 > AEA = 2-AG (Table 2.1). In HEK293 cells stably expressing CB2, HU-
210, CP-55,940, WIN-55,212-2, AEA, and 2-AG also inhibited forskolin-stimulated 
cAMP accumulation in a concentration-dependant manner (Fig. 2.8), with a rank order of 
potency ofHU-210 = CP-55,940 > WIN-55,212-2 > AEA = 2-AG (Table 2.1). 
Screen of a Library of Putative Endocannabinoids and The Structure-Activity 
Relationships of Fatty Acid Ethanolamides in Activating CBl and CB2. 
In an attempt to discover novel ligands for either CB 1 or CB2, and to examine the 
structure-activity relationship of putative endocannabinoids towards these two receptors, 
each compound from a chemical library containing 60 putative endocannabinoids was 
tested for its ability to activate these receptors. Several distinct classes ofligands were 
tested in this screen, including amides, ethanolamides, lipo-amino acids, acyl-GABAs, 
and acyl-dopamines. None of the amides, lipo-amino acids, acyl.,GABAs, and acyl-
dopamines was able to activate either CB 1 or CB2 (Data not shown). In contrast, several 
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compounds in the fatty acid ethanolamide series exhibited agonist activity towards CB 1 
and CB2 (Table 2.2). 
Among the fatty acid ethanolamide series, AEA, Docosatetra-7Z, 1 OZ, 13Z, 16Z-
enoyl ethanolamide (DTEA) and Dihomo-y-linolenoyl ethanol amide (DLEA) activated 
both CB1 and CB2 in a concentration-dependent manner. For CB1 (Fig. 2.9), the potency 
ofDLEA was similar to AEA whereas the potency DTEA was weaker than AEA. For 
CB2 (Fig. 2.10), the rank order of potency is DLEA > DTEA > AEA. In addition, the 
rank order of efficacy is AEA > DLEA = DTEA for CB 1 and AEA > DLEA > DTEA for 
CB2. In contrast, OEA and Linoleoyl ethanolamide (LEA) displayed no agonist activity 
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Figure 2.1. Z' factor determination. The solid symbols represent positive controls (cells 
stimulated with 100 nM CP-55,940), while the open symbols represent negative controls 
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Figure 2.2. Z' factor determination. The solid symbols represent positive controls (cells 
stimulated with 100 nM CP-55,940), while the open symbols represent negative controls 














Figure 2.3. DMSO tolerance. HEK293 cells stably expressing either CB 1 were treated 
with different concentrations of DMSO. Delta F % was calculated using the following 
fonnula: Delta F % = [(standard or sample ratio -- ratio of the negative control) / ratio of 
the negative control] x 100. Data shown represent the mean ± S.E.M. of three 
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Figure 2.4. DMSO tolerance. HEK293 cells stably expressing CB2 were treated with 
different concentrations of DMSO. Delta F % was calculated using the following 
fonnula: Delta F % = [(standard or sample ratio -- ratio of the negative control) I ratio of 
the negative control] x 100. Data shown represent the mean ± S.E.M. of three 
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Figure 2.S. Forskolin concentration optimization. HEK293 cells stably expressing 
CB 1 were treated with different concentrations of forskolin. Data shown represent the 
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Figure 2.6. Forskolin concentration optimization. HEK293 cells stably expressing 
CB2 were treated with different concentrations of forskolin. Data shown represent the 
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Figure 2.7. Pharmacological testing of known cannabinoid agonists. HEK293 cells 
stably expressing CB 1 were treated with different concentrations of cannabinoid agonists 
HU-210, CP-55,940, WIN-55,212-2, 2-arachidonoyl glycerol, and anandamide for 7 
minutes. Results are expressed as percent forskolin-stimulated cAMP accumulation. Data 
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Figure 2.8. Pharmacological testing of known cannabinoid agonists. HEK293 cells 
stably expressing CB2 were treated with different concentrations of cannabinoid agonists 
HU-21O, CP-55,940, WIN-55,212-2, 2-arachidonoyl glycerol, and anandamide for 7 
minutes. Results are expressed as percent forskolin-stimulated cAMP accumulation. Data 
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Figure 2.9. The structure-activity relationships of fatty acid ethanolamides in 
activating CBt. HEK293 cells stably expressing CB 1 were treated with different 
concentrations of oleoyl ethanolarnide (OEA), linolenoyl ethanolamide (LEA), 
docosatetra-7Z, 1 OZ, 13Z, 16Z-enoyl ethanol amide (DTEA), arachidonoyl ethanolamide 
(AEA), and dihomo-y-linolenoyl ethanol amide (DLEA) for 7 minutes. Results are 
expressed as a percentage of forskolin-stimulated cAMP accumulation. Data shown 
represent the mean ± SEM of three independent experiments performed in duplicate. 
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Figure 2.10. The structure-activity relationships of fatty acid ethanolamides in 
activating CB2. HEK293 cells stably expressing CB2 were treated with different 
concentrations of oleoyl ethanolamide (OEA), linolenoyl ethanolamide (LEA), 
docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl ethanolamide (DTEA), arachidonoyl ethanolamide 
(AEA), and dihomo-y-linolenoyl ethanolamide (DLEA) for 7 minutes. Results are 
expressed as a percentage of forskolin-stimulated cAMP accumulation. Data shown 
represent the mean ± SEM of three independent experiments performed in duplicate. 
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Table 2.1. The effects of known cannabinoid agonists on inhibiting forskolin-
stimulated cAMP accumulation in HEK293 cells stably expressing CBI or CB2. 
Drugs CBI- ECso (95% CI) (nM) CB2- ECso (95% CI) (nM) 
HU-210 0.16 (0.03 to 0.695) 3.92 (1.68 to 9.15) 
CP-55,940 4.91 (1.72 to 14.04) 5.15 (3.21 to 8.25) 
WIN-55,212-2 55.36 (25.71 to 119.2) 14.69 (9.11 to 23.69) 
Anandamide 1032 (356 to 3000) 290 (112 to 751) 
2-Arachidonoyl 910 (400 to 2100) 320 (64 to 1600) 
Glycerol 
CI, confidence interval. Data shown are from three experiments, each performed in 
duplicate. 
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Table 2.2. The structure-activity relationships of fatty acid ethanolamides in 
inhibiting forskolin-stimulated cAMP accumulation in HEK293 cells expressing 
CBlorCB2. 
CBl CB2 
Drug ECso (95% CI)(nM) ECso (95% CI) (nM) 
Oleoyl ethanolamide (OEA) NR NR 
Linoleoyl ethanolamide (LEA) NR NR 
Dihomo-gamma-linolenoyl 
ethanolamide (DLEA) 238 (86.1 to 658) 21.4 (13.8 to 33.2) 
Arachidonoyl ethanolamide 
(AEA) 1165 (373 to 3643) 1239 (384 to 3994) 
Docosatetra-7Z, 1 OZ, 13Z, 16Z-
enoyl ethanolamide (DTEA) 1870 (599 to 5837) 149 (86.2 to 258.1) 
CI, confidence interval. NR, No response. Data shown are from three experiments, each 
performed in duplicates. 
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DISCUSSION 
The purpose of this study was two-fold: 1) To optimize a cell-based, HTRF 
cAMP assay for screening novel ligands for the cannabinoid receptors; and 2) To conduct 
a pilot study on a library of 60 putative endocannabinoids to search for novel ligands and 
to investigate the structure-activity relationships of fatty acid ethanolamides for activating 
cannabinoid receptors. 
Agonist binding to CB 1 and CB2 leads to Gi coupling and inhibition of adenylate 
cyclase (Felder et aI., 1995). As a result, there is a decrease in intracellular cAMP levels 
which was measured as an increase in HTRF signal in this study. In this study, we have 
shown that the HTRF HiRange cell-based cAMP assay is a suitable technology for 
screening ligands that may act on CB 1 and CB2. 
The Z'factor is a standard statistical parameter used to evaluate the robustness of 
a screening assay (Zhang et aI., 1999). The Z'factor value can range between 0 and 1, 
with values approaching 1 indicating excellent assay robustness. A value of greater than 
0.5 indicates a suitable difference between signal and background values with low 
variability. In this study we determined Z'factor according to the methods published 
previously (Zhang et aI., 1999). The calculated Z'factors for the cell-based cAMP assay 
for CBl and CB2 receptors were 0.77 and 0.79, respectively (Figs. 2.1,2.2). These 
results demonstrated that this assay is robust and suitable for screening ligands that 
activate both CBl and CB2 since the determined Z'factor is greater than 0.5. 
Since most chemical compound libraries come pre-dissolved in dimethyl 
sulfoxide (DMSO), it is critical to determine the maximum concentration that a 
30 
compound can be screened before DMSO reaches a concentration that is too high to be 
tolerated by the assay. Therefore, we determined the effect of DMSO on the HTRF 
HiRange cAMP cell-based assay. We tested DMSO at a variety of concentrations and the 
results showed that the assay can tolerate DMSO up to 1 % (Figs. 2.3, 2.4). These data 
indicate that the assay is suitable for screening ligands that may act on CB 1 or CB2 at a 
DMSO concentration ofless than 1 %. 
Since the cannabinoid receptors are negatively coupled to adenyl ate cyclase 
(Felder et aI., 1995), it is necessary to first raise the cellular cAMP levels in order to 
observe a robust decrease in cAMP upon ligand binding. Concentration-response studies 
were performed in HEK293 stably expressing CB 1 and HEK293 cells stably expressing 
CB2 to determine the optimal forskolin concentration for our screening assays (Figs. 2.5, 
2.6). Based on our data, for compound screening and testing, 1 j.!M forskolin was used to 
stimulate cAMP production in both the CB I-expressing and the CB2-expressing HEK293 
cells. 
To validate that the HTRF HiRange cell-based cAMP assay is suitable for 
screening ligands that may activate CB 1 and CB2, we performed concentration-response 
studies for five previously reported CBl and CB2 agonists (Figs. 2.7, 2.8). The rank 
order of potencies of these known agonists in inhibiting cAMP levels in both CB 1- and 
CB2-expressing HEK293 cells HU-210 > CP-55,940 > WIN-55,212-2 > AEA = 2-AG 
and HU-210 = CP-55,940 > WIN-55,212-2 > AEA = 2-AG , respectively (Table 2.1). 
These data are consistent with previous reports regarding the potency of these CBl and 
CB2 agonists. These results also confirmed the suitability ofHTRF HiRange cell-based 
cAMP assay for screening potential novel ligands for both CB 1 and CB2. 
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In 1992, Devane et aI. reported AEA, a prototypical N-acyl ethanolamide (Di 
Marzo et aI., 1994), as the first endogenous ligand for CBl (Devane et aI., 1992b). 
Recently, several fatty acid amide derivatives have been identified in mammals in which 
the ethanolamide moiety is replaced by amino acids (glycine and alanine), dopamine or 
GABA to form N-acyl-amino acids (Lipo-amino acids), N-acyl-dopamines, and N-acyl-
GABAs (Connor et aI., 2010). Since these compounds are structurally related to AEA, it 
has been hypothesized that they may activate cannabinoid receptors. However, to our 
knowledge, this hypothesis has not been tested thoroughly by experimental studies. In 
order to test this hypothesis in a systemic and comprehensive manner, in the current study 
we examined 60 putative endocannabinoids from a compound library for their ability to 
activate either CB 1 or CB2. This library is designed as an array of 10 different fatty acids 
and 6 different polar head groups and includes the following classes of ligands: Amides, 
Ethanolamides, Lipo-amino acids, Acyl-dopamines, and Acyl-GABAs. 
Our data demonstrate that none of the Amides, Lipo-amino acids (glycine and 
alanine), Acyl-dopamines, and Acyl-GABAs were able to activate either CBl or CB2 in 
cAMP accumulation assays. Therefore, our data disapprove the hypothesis that these 
compounds are endogenous agonists for either CB 1 or CB2 in cAMP accumulation 
assays. In contrast to our findings using cAMP assays, it has been reported previously 
that N-arachidonoyl dopamine (NADA), one of the acyl-dopamines, was able to bind 
CB 1 receptor and activates calcium mobilization in neuroblastoma cells in a fashion 
consistent with CB 1 recptor activation (Bisogno et aI., 2000). Taken together, this 
suggests that NADA is an agonist on CB 1 for causing calcium mobilization, but not an 
agonist on CB 1 to inhibit adenylate cyclase. This type of ligand-biased signaling has been 
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reported for other ligands ofG-protein coupled receptors (GPCRs) (Kenakin, 2007). It 
has been suggested that GPCRs can adopt multiple conformations, leading to different 
signaling events. Furthermore, it has been postulated that these different conformations 
can be stabilized by different ligands, causing ligand-biased signaling (Kenakin, 2007). 
In addition to AEA, the first identified endogenous agonist for cannabinoid 
receptors, several other endogenous ethanolamides have been isolated and identified in 
mammals (Hanus et aI., 1993). Among these endogenous ethanolamides, DLEA and 
DTEA have been shown to bind CBl (Hanus et aI., 1993). In the current study we have 
shown that DLEA and DTEA display similar potencies for CB 1 in cAMP accumulation 
assays which is consistent with a previous report (Hanus et aI., 1993). In addition, we 
have demonstrated that both of these compounds have similar efficacy as AEA to activate 
CB 1 in the cAMP accumulation assays. Furthermore, we have demonstrated that the 
putative endocannabinoids OEA and LEA do not activate either CBl or CB2. 
Using HEK293 cells stably expressing CB2, we have found that the rank order of 
potency is DLEA > DTEA > AEA, and both DLEA and DTEA have significantly lower 
efficacy than AEA in inhibiting cAMP accumulation. DLEA has previously been 
reported to be essentially equipotent at the CBl and CB2 receptors (Felder et aI., 1995). 
To the best of our knowledge, the agonist activity ofDTEA on CB2 has not been 
reported. In the current study, we have demonstrated that both DLEA and DTEA have 
higher potency on CB2 than on CB 1, thus exhibiting a significant level of CB2 
selectivity. In terms of efficacy, AEA was the most efficacious followed by DTEA then 
DLEA. In addition, our results showed that the putative endocannabinoids OEA and LEA 
do not activate CB2. 
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It has previously been shown that endocannabinoids with increased saturation in 
the acyl chain have decreased affinity for CB 1 (Khanolkar and Makriyannis, 1999). In 
addition it has been suggested that AEA analogs with greater than 3 double bonds exhibit 
significant CB 1 affinity and that the presence of 4 cis bonds is optimal (Khanolkar and 
Makriyannis, 1999). OEA and LEA contain one and two double bonds, respectively, in 
the acyl chain, which could be the reason why both OEA and LEA displayed no agonist 
activity on cannabinoid receptors in cAMP accumulation assays. In contrast, DLEA and 
DTEA have three and four double bonds respectively, which could be the reason that 




OPTIMIZATION, VALIDATION, AND APPLICATION OF A CELL-BASED 
SCREENING TECHNOLOGY FOR SEARCHING FOR NOVEL LIGANDS 
FOR GPRl19 
INTRODUCTION 
GPRl19 is a G protein-coupled receptor (GPCR) predominantly expressed in 
the beta cells of the pancreas and enteroendocrine cells of the gastrointestinal tract 
(Chu et aI., 2007b; Lauffer et aI., 2009; Soga et aI., 2005). GPRl19 is coupled to Gs, 
so upon its activation, there is an enhancement of cAMP levels within the cell (Chu et 
aI., 2007b). It has been shown previously that GPRl19 agonists stimulate insulin 
release by at least two mechanisms (Flock et aI., 2011). The first mechanism is that 
the increase in cAMP signaling directly leads to an enhanced glucose-dependant 
insulin secretion. The second mechanism is that the increase in cAMP signaling 
results in an increased glucagon-like peptide 1 (GLP-1) levels. GLP-1 is an anti-
diabetic hormone which stimulates glucose-dependant insulin secretion and also 
inhibits glucagon secretion, appetite, and delays gastric emptying (Lauffer et aI., 
2008). It has been shown that administration of GPRl19 agonists improves glucose 
tolerance in rodents (Chu et aI., 2007b; Overton et aI., 2006; Soga et aI., 2005). In 
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addition, it has been demonstrated that GPRl19 agonists decrease feeding, body weight 
gain and adiposity in rats (Overton et ai., 2006) Thus, GPRl19 is a highly attractive 
potential therapeutic target for both diabetes and obesity. 
The first purpose of the current study is to develop an assay appropriate for 
searching compounds to discover novel ligands for GPRl19. There are many cAMP 
assays available for screening purposes. Homogenous Time Resolved Fluorescence 
(HTRF) is based on the principle of competition of antibody binding sites between the 
native cAMP produced by cells and the d2-labeled cAMP (Gabriel et ai., 2003). One 
distinct advantage of this assay over the other technologies is HTRF's ratiometric 
measurement. In this assay, measurements are taken at two wavelengths (620 and 655 
nm), which allows for the ratiometric reduction of data. The donor (Eu3+ Cryptate) emits 
at 620 nm while the acceptor (d2) emits at 665 nm. The donor measurement serves as an 
internal reference while emissions from acceptor are indicators of biological reaction. 
Homology clustering analysis revealed that the closest relatives of GPRl19 are 
the cannabinoid receptors (Overton et ai., 2006). A separate group confirmed, through 
phylogenetic analysis, that the closest relatives of GPRl19 are the cannabinoid receptors 
and placed GPRl19 to the MECA (melanocortin; endothelial differentiation gene; 
cannabinoid; adenosine) receptor cluster (Godlewski et ai., 2009). Based on these 
observations, it has been hypothesized that synthetic cannabinoid ligands and fatty acid 
amides related to endocannabinoid AEA may be potential ligands for GPRl19. 
Previously, a number of cannabinoid ligands and fatty-acid amides have been 
tested as potential agonists for GPRl19 (Overton et ai., 2006). However, the data from 
different research groups have not always been consistent. For example, Overton and 
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coworkers identified OEA as an endogenous GPRl19 ligand (Overton et aI., 2006). 
However, others found that OEA does not activate GPRl19 (Brown, 2007). 
It has been proposed that 1) unsaturation in the fatty acid acyl chain might be 
important for activating GPRl19; and 2) there is a broad permissiveness in the amine-
derived moieties (the head groups) of lipid amides for being an agonist for GPR119 (Chu 
et aI., 2010). However, these hypotheses either have not been examined by different 
research groups or have not been tested comprehensively using novel ligands. Therefore, 
the second purpose of this study is to re-examine the activity of a number of cannabinoid 
ligands and fatty acid amides towards GPRl19, and to investigate, using novel 
compounds that have never been tested on GPRl19, the structure-activity relationships of 
the acyl side chains as well as the charged head groups in fatty acid amides for activating 
GPRl19. 
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MATERIALS AND METHODS 
Materials 
Dulbecco's Modified Eagles's Medium (DMEM), penicillin/streptomycin, L-
glutamine, trypsin, and geneticin were purchased from Mediatech (Manassas, VA). Fetal 
Bovine Serum was obtained from Atlanta Biologicals (Lawrenceville, GA). Glass tubes 
used for cAMP accumulation assays were obtained from Kimble Chase (Vineland, NJ). 
These tubes were silanized by exposure to dichlorodimethylsilane (Sigma-Aldrich, St. 
Louis, MO) vapor for 3 h under vacuum. 384-well, round bottom, low volume white 
plates were purchased from Grenier Bio One (Monroe, NC). A cell-based cAMP 
HiRange kit was purchased from CisBio International (Bedford, MA). 
CP-55,940, WIN-55,212-2, HU-210, 2-arachidonoyl glycerol, virodhamine, and 
anandamide were purchased from Tocris Bioscience (Ellisville, MO). Forskolin was 
obtained from Sigma (St. Louis, MO). AR231453, R020-1724 and palmitoyl 
ethanolamide were purchased from Enzo Life Sciences (Farmingdale, NY). PSN632408, 
Oleoylethanolamide, linoleoyl ethanolamide, dihomo-gamma-linolenoyl ethanol amide, 
docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl ethanolamide, eicosapentaenoyl ethanol amide, 
docosahexaenoyl ethanolamidel, abnormal cannabidiol, JWH200, JWHOI5, arachidonoyl 
glycine, 0-1602 and 0-1918 were purchased from Cayman Chemical Company (Ann 
Arbor, Michigan). N-oleoyl glycine and N-oleoyl dopamine were purchased from 
Cayman Chemical Company (Ann Arbor, Michigan). Oleamide was purchased from 
Tocris Bioscience (Ellisville, MO). 
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Cell Transfection and Culture 
Human Embryonic Kidney 293 (HEK293) cells were maintained in Dulbecco's 
Modified Eagle Medium (DMEM) containing 10% fetal bovine serum, 2mM glutamine, 
100units/ml penicillin, and 1 00 ~glml streptomycin in a humidified atmosphere 
consisting of 5% CO2 at 37°C. Expression plasmid containing the GPRl19 receptor was 
stably transfected into HEK293 cells using lipofectamine, according to manufacturer's 
instructions. Stably transfected cells were selected in culture medium containing 
800~glml geneticin and maintained in growth medium containing 400 ~glml of geneticin 
(G418) until needed for experiments. 
Cell-based HTRF cAMP assay 
Cellular cAMP levels were measured using reagents supplied by Cisbio 
International (HTRF HiRange cAMP kit). Cultured cells were washed twice with 
phosphate-buffered saline (8.1 mM NaH2P04, 1.5 mM KH2P04, 138 mM NaCl, and 2.7 
mM KCI, pH 7.2), and then dissociated in phosphate-buffered saline containing 1 mM 
EDT A. Dissociated cells were collected by centrifugation for 5 min at 2000g. The cells 
were resuspended in cell buffer (DMEM plus 0.2 % fatty acid free bovine serum 
albumin) and centrifuged a second time at 2000g for 5 min at 4°C. Subsequently, the 
cells were resuspended in an appropriate final volume of cell buffer plus the 
phosphodiesterase inhibitor R020-1724 (2 ~M). 5000 cells were added at 5~1 per well 
into 384-well, round bottom, low volume white plates (Grenier Bio One, Monroe, NC). 
Compounds were diluted in drug buffer (DMEM plus 2.5 % fatty acid free bovine serum 
albumin) and added to the assay plate at 5 ~l per well. Following incubation of cells with 
the drugs or vehicle for 30 minutes at room temperature, D2-conjugated cAMP and 
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Europium cryptate-conjugated anti-cAMP antibody were added to the assay plate at 5 III 
per well. After 2 hour incubation at room temperature, the plate was read on a TECAN 
GENious Pro microplate reader with excitation at 337 nm and emissions at 665 nm and 
620nm. 
Statistical Analysis 
Data analyses were performed based on the ratio of fluorescence intensity of each 
well at 620nm and 665 nm. Data are expressed as delta F%, which is defined as 
[(standard or sample ratio - ratio of the negative control) / ratio of the negative control] x 
100. The standard curves were generated by plotting delta F% versus cAMP 
concentrations using non-linear least squares fit (Prism software, GraphPad, San Diego, 
CA). Unknowns are determined from the standard curve as nanomolar concentrations of 
cAMP. After the unknowns are determined, the sigmoidal concentration-response 




Z' factor Determination 
To determine the Z' value, experiments were performed in 384-well plates 
using many replicates of the HTRF cell-based cAMP assay with positive and negative 
controls (Fig. 3.1 ). For positive controls, the HEK293 cells expressing GPRl19 were 
treated with the potent GPR1l9 agonist AR231453 at a concentration of 10 flM for 
30 minutes at room temperature. For negative controls, the cells were treated with 
vehicle for 30 minutes. The Z' value was calculated using the formula: Z' = 1-
3[(standard deviation of negative control) + standard deviation of positive control)]/ 
[(mean of negative control) - (mean of positive control)] (Zhang et aI., 1999). In the 
current study, the Z factor was determined to be 0.68. 
Tolerance to Dimethyl Sulfoxide (DMSO) 
One important condition to define is the concentration of dimethyl sulfoxide 
(DMSO) that the HTRF cAMP assay is able to tolerate without any loss in signal. For 
this purpose, we tested the effect of DMSO at concentrations ranging from 0.001% to 
100 %. As shown in Fig. 3.2, the HTRF cAMP assay can tolerate DMSO up to 1% 
without any loss of signal. 
Pharmacological Testing of Known GPR119 Agonists 
The ability of known agonists to activate GPRl19 was tested in a functional 
HTRF cAMP accumulation assay via HEK293 cells stably expressing GPRl19. As 
shown in Fig. 3.3 and Table 3.1, all three previously reported GPRl19 ligands, 
AR231453 (Semple et aI., 2008), OEA (Overton et aI., 2006), and PSN632408 
(Overton et aI., 2006), increase the cellular cAMP levels in a concentration-dependent 
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manner, with a rank order of potency of AR231453 > OEA > PSN632408, and a rank 
order of efficacy of AR231453 > OEA = PSN632408. 
The Effects of Synthetic Cannabinoid Ligands on GPRl19 
Three synthetic cannabinoids, CP-55,940, HU-210, and WIN-55,212-2, were 
tested for their activity towards GPRl19. As shown in Table 3.2, HU-210 and CP-
55,940, and WIN-55,212-2 did not activate GPRl19. 
The Effects of Acyl Chain Unsaturation on the Ability of Fatty Acid 
Ethanolamides to Activate GPRl19 
Three endogenous fatty acid ethanolamides, OEA, PEA and AEA, were tested 
for their activity on GPRl19 (Fig. 3.4 and Table 3.3). All three compounds increased 
cAMP levels, with ECso values not significantly different from each other. However, 
our results demonstrated that OEA was the most efficacious, followed by PEA and 
then AEA. 
In this study, we examined the structure activity relationship on a subset of 
fatty acid ethanolamides (Fig. 3.5 and Table 3). Among fatty acid ethanolamides that 
we tested, LEA, and DLEA were found to be the most efficacious towards GPRl19 
(Fig. 3.5). In terms of acyl chain unsaturation, LEA and DLEA contain two and three 
double bonds, respectively. These two compounds had efficacy similar to those of 
OEA, a putative endogenous GPRl19 ligand which contains one double bond. 
On the contrary, Docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl ethanol amide (DTEA), 
Eicosapentaenoyl ethanolamide (EPEA) and Docosahexaenoyl ethanolamide (DHEA) 
were found to have significantly reduced efficacy towards GPRl19 than OEA (Fig. 
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3.5). DTEA, EPEA and DHEA contain four, five, and six double bonds in their fatty 
acid acyl chain, respectively. 
The effects of different head groups on the ability of oleoyl amides to activate 
GPR119. 
We hypothesized that different head groups on the oleoyl amides may impact 
the ability of oleoyl amides to activate GPRl19. To test this hypothesis, N-
oleoyldopamine (OLDA), oleamide, OEA, oleoyl alanine, oleoyl glycine, and oleoyl 
GABA were tested for their ability to increase cAMP levels in HEK293 cells stably 
expressing GPRl19. 
Fig. 3.6 and Table 3.4 demonstrate the agonist activity of different oleoyl 
amides as compared to OEA. In HEK293 cells stably expressing GPRl19, OLDA, 
Oleamide, and OEA increased cAMP levels, with similar ECso and Emax values. On 
the contrary, oleoyl alanine, oleoyl glycine, and oleoyl GABA failed to activate 
GPRl19 with concentrations up to 10 !J.M. 
43 






O+------,------,-----~~----~----~~----~ o 10 20 30 
Wells 
40 50 60 
Figure 3.1. Z' factor determination. Open symbols represent positive controls (cells 
stimulated with 10 IlM AR231453), while solid symbols represent negative controls 
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Figure 3.2. DMSO tolerance. HEK293 cells stably expressing GPRl19 was treated with 
different concentrations of DMSO. Delta F % was calculated using the following 
fonnula: Delta F % = [(standard or sample ratio - ratio of the negative control) / ratio of 
the negative control] x 100. Values represent the mean ± S.E.M. of three independent 
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Figure 3.3. Pharmacological testing of known GPR119 agonists. HEK293 stably 
expressing GPRl19 were treated with GPR119 agonists AR231453, oleoylethanolamide, 
and PSN632408 for 30 minutes. Results are expressed as actual cAMP levels determined 
from the standard curve. Values represent the mean ± S.E.M. of three independent 
experiments, each performed in duplicate. 
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Figure 3.4. The effects of acyl chain unsaturation on the ability of fatty acid 
ethanolamides to activate GPR119. HEK293 stably expressing GPRl19 were treated 
with OEA, PEA, and AEA for 30 minutes. Results are expressed as actual cAMP levels 
determined from the standard curve. Values represent the mean ± S.E.M. of three 
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Figure 3.5. The effects of acyl chain unsaturation on the ability of fatty acid 
ethanolamides to activate GPR119. HEK293 stably expressing GPRl19 were treated 
with Oleoyl ethanolamide (OEA), Linoleoyl ethanolamide (LEA), Dihomo-gamma-
linolenoyl ethanolamide (DLEA), Docosatetra-7Z, 1 OZ, 13Z, 16Z-enoyl ethanol amide 
(DTEA), Eicosapentaenoyl ethanol amide (EPEA) and Docosahexaenoyl ethanolamide 
(DHEA) for 30 minutes. Results are expressed as actual cAMP levels determined from 
the standard curve. Values represent the mean ± S.E.M. of three independent experiments 
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Figure 3.6. The effects of different head groups on the ability of oleoyl amides to 
activate GPR119. HEK293 stably expressing GPRl19 were treated with OLDA, 
oleamide, OEA, oleoyl alanine, oleoyl glycine, and oleoyl GABA for 30 minutes. Results 
are expressed as actual cAMP levels determined from the standard curve. Values 
represent the mean ± S.E.M. of three independent experiments each performed in 
duplicate. 
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Table 3.1. Effect of known GPR1l9 agonists on increasing cAMP in HEK293 cells 
stably expressing GPRl19. 
Drug ECso (95% CI) (IJM) 
AR231453 .027 (0.013 to 0.058) 
PSN632-408 1.28 (1.10 to 1.49) 
Oleoylethanolamide 1.08 (0.59 to 1.98) 
CI, confidence interval. Data shown are from three experiments each performed in 
duplicate. 
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Table 3.2. The effects of synthetic cannabinoids on increasing cAMP levels in 
HEK293 cells stably expressing GPR119. 




CI, confidence interval. NR, No response. Data shown are from experiments each 
performed in duplicate. 
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Table 3.3. The effects of acyl chain unsaturation on the ability of fatty acid 
ethanolamides to increase cAMP levels in HEK293 cells stably expressing GPR119. 
Drug ECso (95% CI) (,..M) 
Linoleoyl ethanol amide 4.33 (1.48 to 12.7) 
Docosahexaenoyl ethanol amide NR 
Dihomo-y-linolenoyl ethanolamide 8.38 (0.91 to 77.2) 
Docosatetra-7Z,1 OZ, 13Z, 16Z-enoyl 6.02 (1.93 to 18.8) 
ethanolamide 
Eicosapentaenoyl ethanolamide 5.09 (0.59 to 44.0) 
Oleoylethanolamide 1.08 (0.59 to 1.98) 
Anandamide 2.62 (0.36 to 19.3) 
Palmi toylethanolamide 6.82 (1.10 to 42.5) 
CI, confidence interval. NR, No response. Data shown are from at least three experiments 
each performed in duplicate. 
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Table 3.4. The effects of different head groups on the ability of oleoyl amides to 
increase cAMP levels in HEK293 cells stably expressing GPR119. 
Drugs ECso (95% CI) (IlM) 
OLDA 1.17 (0.98 to 1.38) 
Oleamide 1.28 (1.1 0 to 1.49) 
OEA 1.08 (0.59 to 1.98) 
Oleoyl alanine NR 
Oleoyl glycine NR 
Oleoyl GABA NR 
CI, confidence interval. NR, No response. Data shown are from experiments each 
performed in duplicate. 
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DISCUSSION 
Agonist binding to GPR 119 leads to Gs coupling and activation of adenylate 
cyclase (Chu et aI., 2007b). As a result, there is an increase in intracellular cAMP levels 
which was measured as a decrease in HTRF signal in this study. We have shown that the 
HTRF HiRange cell-based cAMP assay is a suitable technology for screening ligands that 
may act on GPRl19. 
The Z'factor is a standard statistical parameter used to evaluate the robustness of 
a screening assay (Zhang et aI., 1999). The Z'factor value can range between 0 and 1, 
with values approaching 1 indicates excellent assay robustness. A value of greater than 
0.5 indicates a suitable difference between signal and background values with low 
variability. In this study we determined Z'factor according to the methods published 
previously (Zhang et aI., 1999). The calculated Z'factor for the HTRF HiRange cell-
based cAMP assay was 0.68. These results demonstrated that this assay is robust and 
suitable for screening ligands that activate GPRl19 since the determined Z'factor is 
greater than 0.5. 
Since most chemical compound libraries come pre-dissolved in dimethyl 
sulfoxide (DMSO), it is critical to determine the maximum concentration that a 
compound can be screened before DMSO reaches a concentration that is too high to be 
tolerated by the assay. Therefore, we determined the effect of DMSO on the HTRF 
HiRange cAMP cell-based assay. We tested DMSO at a variety of concentrations and the 
results showed that the assay can tolerate DMSO up to 1 %. These data indicate that the 
assay is suitable for screening ligands that may act on GPRl19 at a DMSO concentration 
of less than 1 %. 
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To validate that the HTRF HiRange cell-based cAMP assay is suitable for 
screening ligands that may activate GPRI19, we performed concentration-response 
studies for three previously reported GPR119 agonists. The rank order of potencies of 
these three known GPR119 agonists in enhancing cAMP levels in GPRl19-expressing 
HEK293 cells was AR231453 > OEA = PSN632408. These data are consistent with 
previous reports regarding the potency of these GPR119 agonists (Overton et aI., 2006; 
Semple et aI., 2008). These results also confirmed the suitability ofHTRF HiRange cell-
based cAMP assay for screening potential novel ligands for GPRI19. 
Since the closest relatives of GPR 119 are the cannabinoid receptors (Godlewski et 
aI., 2009), in this study we tested the three prototypic synthetic cannabinoid agonists CP-
55,940, HU-210, and WIN-55,212-2 for their potential activity towards GPR119 using 
the HTRF HiRange cAMP cell-based assay. Similar to the data reported by Overton et aI. 
(2006), our study showed that the classical cannabinoid agonist HU-21O, the non-
classical, the bicyclic cannabinoid agonist CP-55,940, and the aminoalkylindole WIN-
55,212-2 do not activate GPRI19. 
Recently, the fatty acid ethanolamide OEA has been reported to be a putative 
endogenous ligand for GPR119 (Overton et aI., 2006). Overton and coworkers have also 
tested the endogenous cannabinoid agonist AEA and the saturated fatty-acid 
ethanol amide PEA for GPR119 activity in a yeast-based assay. Their results showed that 
OEA was the most efficacious, followed by PEA and then AEA. As shown by the 
concentration-response curves in this study, our results on OEA, PEA, and AEA are very 
much consistent with those reported by Overton et aI. (2006). 
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Previously, based on the data with OEA, PEA, and AEA, Overton and co-workers 
have proposed that unsaturation in fatty acid aryl chain might be important for activating 
GPRl19 (Overton et aI., 2006) . 
In this study, we report for the first time the structure activity relationship for 
GPRl19 activation on a subset of fatty acid ethanolamides, including linoleoyl 
ethanolamide (LEA), dihomo-gamma-linolenoyl ethanolamide (DLEA), docosatetra-
7Z,1 OZ, 13Z, 16Z-enoyl ethanolamide (DTEA), eicosapentaenoyl ethanol amide (EPEA), 
and docosahexaenoyl ethanolamide (DHEA). Overall, our new data in the present study 
provide direct evidence to further support the hypothesis that unsaturation in the acyl 
chain of fatty acid ethanolamides affects the ability of these compounds to activate 
GPRl19. 
Our results indicate that increasing unsaturation reduces the ability of these 
ligands to activate GPRl19; with compounds containing 1-3 double bonds have 
significantly higher efficacy and potency than those compounds containing 4-6 double 
bonds. 
Chu et ai. (2010) reported that a diverse set oflipid amides, including OLDA and 
oleamide, activate GPRl19. Thus, they suggested that there is a broad permissiveness in 
the amine-derived moieties (the head groups) oflipid amides for being an agonist for 
GPR119 (Chu et aI., 2010). In the present study, we demonstrated that both OLDA and 
oleamide activate GPRl19, with similar potency and efficacy as OEA. These data are 
consistent with the findings of Chu et ai. (2010) and confirm the notion that there is a 
considerable level of permissiveness in the head group of oleoyl amides. 
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However, in the current study, we also demonstrated that oleoyl alanine, oleoyl 
glycine, and oleoyl GABA were unable to activate GPRl19. These data suggest that 
although there are certain levels of permissiveness, in order to activate GPRl19, there are 
also certain structural requirements for the head groups of oleoyl amides. An interesting 
observation is that all three compounds (oleoyl alanine, oleoyl glycine, and oleoyl 
GABA) that failed to activate GPRl19 have a carboxcylic group. This suggests that the 
reason that these ligands failed to activate GPRl19 might be due to either the spatial 
hindrance or the acidic nature of the carboxylate group. 
Among the three oleoyl amides that activated GPRl19, both OLDA and OEA 
contain hydrogen donating hydroxyl groups in their structure for potential hydrogen 
bonding interactions with the receptor. This indicates that these hydrogen donating 
groups might be important for their ability to interact and activate GPRl19. 
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